Nurix Therapeutics Inc
$ 25.22
0.40%
06 Aug - close price
- Market Cap 2,606,996,000 USD
- Current Price $ 25.22
- High / Low $ 25.49 / 24.57
- Stock P/E N/A
- Book Value 3.88
- EPS -3.52
- Next Earning Report 2026-10-08
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.40 %
- ROE -0.80 %
- 52 Week High 25.49
- 52 Week Low 8.20
About
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company is headquartered in San Francisco, California.
Analyst Target Price
$33.12
Quarterly Earnings
| May 2026 | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | Nov 2023 | Aug 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-09 | 2026-04-08 | 2026-01-28 | 2025-10-09 | 2025-07-09 | 2025-04-08 | 2025-01-28 | 2024-10-11 | 2024-07-11 | 2024-04-10 | 2024-02-15 | 2023-10-12 |
| Reported EPS | -0.81 | -0.79 | -0.82 | -1.03 | -0.52 | -0.67 | -0.75 | -0.67 | -0.71 | -0.76 | -0.77 | -0.68 |
| Estimated EPS | -0.73 | -0.8295 | -0.92 | -0.85 | -0.74 | -0.76 | -0.6689 | -0.68 | -0.63 | -0.8 | -0.5 | -0.74 |
| Surprise | -0.08 | 0.0395 | 0.1 | -0.18 | 0.22 | 0.09 | -0.0811 | 0.01 | -0.08 | 0.04 | -0.27 | 0.06 |
| Surprise Percentage | -10.9589% | 4.7619% | 10.8696% | -21.1765% | 29.7297% | 11.8421% | -12.1244% | 1.4706% | -12.6984% | 5% | -54% | 8.1081% |
Next Quarterly Earnings
| Aug 2026 | |
|---|---|
| Reported Date | 2026-10-08 |
| Fiscal Date Ending | 2026-08-31 |
| Estimated EPS | -0.61 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NRIX
2026-08-06 00:10:09
Nurix Therapeutics insider Gwenn Hansen sold 4,356 shares of NRIX stock for $108,900 at $25 per share, reducing her ownership by 3.58%. This transaction occurred under a pre-arranged Rule 10b5-1 plan, leaving her with 117,227 shares. Despite a quarterly loss and missed revenue estimates, the company has made pipeline progress, including a $10 million milestone payment for a Phase 1 trial initiation and first-patient enrollment in a Phase 3 leukemia trial, leading analysts to maintain a "Moderate Buy" rating with an average price target of $34.
2026-08-05 18:41:42
Nurix Therapeutics Inc. (NRIX) stock hit a 52-week high, closing at $25.22, marking a 140.54% increase over the past year and a 55% gain in the last six months. This surge is likely driven by strong investor confidence and strategic developments, including a significant collaboration deal with Roche for bexdeg. Analysts from Mizuho, Truist Securities, Baird, and Morgan Stanley have all raised their price targets for Nurix, maintaining positive ratings.
2026-08-05 17:17:09
Nurix Therapeutics (NRIX) has announced a $10 million milestone payment from Sanofi for the first-in-human trial of an oral STAT6 degrader and the enrollment of the first patient in a pivotal Phase 3 trial for bexobrutideg with Roche. These developments highlight Nurix's progress in targeted protein degradation and its expanded collaborations with major pharmaceutical companies. Despite the positive news, analysts note risks including expected earnings decline and shareholder dilution.
2026-08-05 16:10:09
Nurix Therapeutics (NASDAQ:NRIX) recently hit a new 52-week high of $25.40 after announcing a $10 million milestone payment from Sanofi and the initiation of a Phase 3 trial for bexobrutideg. Despite positive analyst sentiment, with a consensus "Moderate Buy" rating and a $34 price target, the company remains unprofitable and missed recent EPS and revenue estimates. Insider selling, though under pre-arranged plans, also occurred, raising some bearish concerns.
2026-08-05 13:42:43
Nurix Therapeutics (NRIX) stock has reached a 52-week high, closing at $25.22, signifying a 140.54% increase over the past year. This performance, including a 118% total return, is supported by strong investor confidence and recent positive analyst updates following the company's Q2 2026 earnings report and a significant collaboration deal with Roche. Despite appearing slightly overvalued according to InvestingPro, analysts from Mizuho, Truist Securities, Baird, and Morgan Stanley have all raised their price targets, maintaining positive ratings.
2026-08-05 13:42:43
Gwenn Hansen, an insider at Nurix Therapeutics (NASDAQ:NRIX), sold 4,111 shares of the company's stock for approximately $100,144 under a Rule 10b5-1 plan, reducing her ownership by 3.39%. This transaction follows previous sales in July and June. Despite the insider selling, analysts maintain a "Moderate Buy" rating for NRIX with a consensus price target of $34, even though the company recently missed quarterly earnings and revenue expectations.
